PARIS--(BUSINESS WIRE)--Covidien’s Stellarex™ drug-coated angioplasty balloon (Stellarex DCB) continues to be shown as safe and effective for treatment of peripheral arterial disease (PAD), according to new 24-month data released today from the company’s ILLUMENATE First-in-Human (FIH) Study. The Stellarex DCB uses EnduraCoat™ technology, a durable, uniform balloon coating designed to prevent drug loss during transit and facilitate controlled, efficient drug delivery to the treatment site. The FIH study results were reported at the EuroPCR Scientific Congress in Paris, held May 20-23, 2014.
Help employers find you! Check out all the jobs and post your resume.
